<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>467</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15365188</PubmedId>
            <Abstract>The Wilms' tumor gene WT1 is overexpressed in leukemias and various types of solid tumors, and the WT1 protein was demonstrated to be an attractive target antigen for immunotherapy against these malignancies. Here, we report the outcome of a phase I clinical study of WT1 peptide-based immunotherapy for patients with breast or lung cancer, myelodysplastic syndrome, or acute myeloid leukemia. Patients were intradermally injected with an HLA-A*2402-restricted, natural, or modified 9-mer WT1 peptide emulsified with Montanide ISA51 adjuvant at 0.3, 1.0, or 3.0 mg per body at 2-week intervals, with toxicity and clinical and immunological responses as the principal endpoints. Twenty-six patients received one or more WT1 vaccinations, and 18 of the 26 patients completed WT1 vaccination protocol with three or more injections of WT1 peptides. Toxicity consisted only of local erythema at the WT1 vaccine injection sites in patients with breast or lung cancer or acute myeloid leukemia with adequate normal hematopoiesis, whereas severe leukocytopenia occurred in patients with myelodysplastic syndrome with abnormal hematopoiesis derived from WT1-expressing, transformed hematopoietic stem cells. Twelve of the 20 patients for whom the efficacy of WT1 vaccination could be assessed showed clinical responses such as reduction in leukemic blast cells or tumor sizes and/or tumor markers. A clear correlation was observed between an increase in the frequencies of WT1-specific cytotoxic T lymphocytes after WT1 vaccination and clinical responses. It was therefore demonstrated that WT1 vaccination could induce WT1-specific cytotoxic T lymphocytes and result in cancer regression without damage to normal tissues.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>13885-90</ArticlePages>
            <ArticleTitle>Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Oka</LastName>
                    <ForeName>Yoshihiro</ForeName>
                </Author>
                <Author>
                    <LastName>Tsuboi</LastName>
                    <ForeName>Akihiro</ForeName>
                </Author>
                <Author>
                    <LastName>Taguchi</LastName>
                    <ForeName>Tetsuya</ForeName>
                </Author>
                <Author>
                    <LastName>Osaki</LastName>
                    <ForeName>Tadashi</ForeName>
                </Author>
                <Author>
                    <LastName>Kyo</LastName>
                    <ForeName>Taiichi</ForeName>
                </Author>
                <Author>
                    <LastName>Nakajima</LastName>
                    <ForeName>Hiroko</ForeName>
                </Author>
                <Author>
                    <LastName>Elisseeva</LastName>
                    <ForeName>Olga A</ForeName>
                </Author>
                <Author>
                    <LastName>Oji</LastName>
                    <ForeName>Yusuke</ForeName>
                </Author>
                <Author>
                    <LastName>Kawakami</LastName>
                    <ForeName>Manabu</ForeName>
                </Author>
                <Author>
                    <LastName>Ikegame</LastName>
                    <ForeName>Kazuhiro</ForeName>
                </Author>
                <Author>
                    <LastName>Hosen</LastName>
                    <ForeName>Naoki</ForeName>
                </Author>
                <Author>
                    <LastName>Yoshihara</LastName>
                    <ForeName>Satoshi</ForeName>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Fei</ForeName>
                </Author>
                <Author>
                    <LastName>Fujiki</LastName>
                    <ForeName>Fumihiro</ForeName>
                </Author>
                <Author>
                    <LastName>Murakami</LastName>
                    <ForeName>Masaki</ForeName>
                </Author>
                <Author>
                    <LastName>Masuda</LastName>
                    <ForeName>Tomoki</ForeName>
                </Author>
                <Author>
                    <LastName>Nishida</LastName>
                    <ForeName>Sumiyuki</ForeName>
                </Author>
                <Author>
                    <LastName>Shirakata</LastName>
                    <ForeName>Toshiaki</ForeName>
                </Author>
                <Author>
                    <LastName>Nakatsuka</LastName>
                    <ForeName>Shin-Ichi</ForeName>
                </Author>
                <Author>
                    <LastName>Sasaki</LastName>
                    <ForeName>Ayako</ForeName>
                </Author>
                <Author>
                    <LastName>Udaka</LastName>
                    <ForeName>Keiko</ForeName>
                </Author>
                <Author>
                    <LastName>Dohy</LastName>
                    <ForeName>Hiroo</ForeName>
                </Author>
                <Author>
                    <LastName>Aozasa</LastName>
                    <ForeName>Katsuyuki</ForeName>
                </Author>
                <Author>
                    <LastName>Noguchi</LastName>
                    <ForeName>Shinzaburo</ForeName>
                </Author>
                <Author>
                    <LastName>Kawase</LastName>
                    <ForeName>Ichiro</ForeName>
                </Author>
                <Author>
                    <LastName>Sugiyama</LastName>
                    <ForeName>Haruo</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Molecular Medicine, Osaka University Graduate School of Medicine, Suita City, Osaka 565-0871, Japan.</Affiliations>
            <ArticleChemicalList>Cancer Vaccines;Peptide Fragments;WT1 Proteins</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Substitution; Breast Neoplasms(diagnostic imaging; immunology; pathology); Cancer Vaccines(toxicity); Female; Gene Expression Regulation, Neoplastic(immunology); Genes, Wilms Tumor; Humans; Japan; Kidney Neoplasms(immunology); Neoplasms(immunology); Peptide Fragments(chemistry; immunology); Radiography; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes, Cytotoxic(immunology); WT1 Proteins(genetics; immunology); Wilms Tumor(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>101</Volume>
                <Issue>38</Issue>
                <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
                <Issn>0027-8424</Issn>
                <MedlineTa>Proc Natl Acad Sci U S A</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>WT1</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>CMTWNQMNL</LinearSequence>
                        <StartingPosition>235</StartingPosition>
                        <EndingPosition>243</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P19544.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 13886</LocationOfData>
                <EpitopeId>6671</EpitopeId>
                <ReferenceStartingPosition>235</ReferenceStartingPosition>
                <ReferenceEndingPosition>243</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <TCellId>2537</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>215</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:162</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>CMTWNQMNL</LinearSequence>
                                            <StartingPosition>235</StartingPosition>
                                            <EndingPosition>243</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P19544.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>WT1</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Montanide ISA-51</Adjuvant>
                                <Route>Intradermal</Route>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Disease Names: Immunized patients had breast cancer, lung cancer, and leukemia.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>215</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>WT1</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CMTWNQMNL</LinearSequence>
                                        <StartingPosition>235</StartingPosition>
                                        <EndingPosition>243</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P19544.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Immunological responses were defined as positive when the frequencies of WT1-specific CTLs (determined by tetramer assay) increased by 1.5 times at one time point or more after the WT1 vaccination when compared to WT1-specific CTLs before the WT1 vaccination.  This occurred in 5 out of 15 patients.  The modified 9-mer WT1 peptide was shown to induce much stronger CTL activity than the natural peptide against WT1-expressing tumor cells. This occurred in 8/11 patients.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <TCellId>2590</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>215</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:162</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>CMTWNQMNL</LinearSequence>
                                            <StartingPosition>235</StartingPosition>
                                            <EndingPosition>243</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P19544.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>WT1</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Montanide ISA-51</Adjuvant>
                                <Route>Intradermal</Route>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>Disease Name: Immunized patients had breast cancer, lung cancer, and leukemia.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>215</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>WT1</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>CMTWNQMNL</LinearSequence>
                                        <StartingPosition>235</StartingPosition>
                                        <EndingPosition>243</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P19544.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Immunological responses were defined as positive when the frequencies of WT1-specific CTLs (determined by tetramer assay) increased by 1.5 times at one time point or more after the WT1 vaccination when compared to WT1-specific CTLs before the WT1 vaccination. This occurred in 8/11 patients.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Modified WT1</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>CYTWNQMNL</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Page 13886</LocationOfData>
                <EpitopeId>7446</EpitopeId>
                <ReferenceStartingPosition>235</ReferenceStartingPosition>
                <ReferenceEndingPosition>243</ReferenceEndingPosition>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Modified 9-mer WT1 peptide, in which Y was substitutedfor M at amino acid position 2 (anchor position) of thenatural WT1.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <TCellId>2595</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>CYTWNQMNL</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Modified WT1</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Montanide ISA-51</Adjuvant>
                                <Route>Intradermal</Route>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>Disease Name:  Immunized patients had breast cancer, lung cancer, and leukemia.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>215</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Modified WT1</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <SequenceMoleculeNoNaturalSource>
                                        <ChemicalType>Peptide, no natural source</ChemicalType>
                                        <LinearSequence>CYTWNQMNL</LinearSequence>
                                    </SequenceMoleculeNoNaturalSource>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>15</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>33.3</ResponseFrequency>
                            <AssayComments>Immunological responses were defined as positive when the frequencies of WT1-specific The modified 9-mer WT1 peptide was shown to induce much stronger CTL activity than the natural peptide against WT1-expressing tumor cells.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <TCellId>2594</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>215</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:162</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>CYTWNQMNL</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Modified WT1</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Montanide ISA-51</Adjuvant>
                                <Route>Intradermal</Route>
                            </SecondInVivoProcess>
                            <ImmunizationComments>Disease Name:  Immunized patients had breast cancer, lung cancer, and leukemia.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>215</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Modified WT1</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <SequenceMoleculeNoNaturalSource>
                                        <ChemicalType>Peptide, no natural source</ChemicalType>
                                        <LinearSequence>CYTWNQMNL</LinearSequence>
                                    </SequenceMoleculeNoNaturalSource>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Immunological responses were defined as positive when the frequencies of WT1-specific CTLs (determined by tetramer assay) increased by 1.5 times at one time point or more after the WT1 vaccination when compared to WT1-specific CTLs before the WT1 vaccination.  This occurred in 5 out of 15 patients.  The modified 9-mer WT1 peptide was shown to induce much stronger CTL activity than the natural peptide against WT1-expressing tumor cells.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

